Is JUNS or KAPA more undervalued in 2026?

CirclFi compares Jupiter Neurosciences, Inc. (JUNS) and Kairos Pharma, Ltd. (KAPA) using 13 institutional-grade valuation models. JUNS has a Quality of Company score of 4.7/10 while KAPA scores 4.6/10.

Which is a better buy — JUNS or KAPA?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do JUNS and KAPA valuations compare?

JUNS at $0.26 and KAPA at $0.51 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

JUNS vs KAPA Valuation Comparison 2026 — Intrinsic Value Analysis

JUNS

Pharmaceutical Preparations

Jupiter Neurosciences, Inc.

Quality

4.7

out of 10

Value Trap

—

Price

$0.26

Last close

Models

10/13

Active

KAPA

Pharmaceutical Preparations

Kairos Pharma, Ltd.

Quality

4.6

out of 10

Value Trap

SAFE

Price

$0.51

Last close

Models

7/13

Active

Model-by-Model Comparison

Model	Type	JUNS Fair Value	JUNS Upside	KAPA Fair Value	KAPA Upside
Bayesian DCF	Intrinsic	$0.10	-60.6%	$0.19	-62.4%
Earnings Power Value	Intrinsic	$0.02	-94.6%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$0.04	-83.1%	$0.23	-55.4%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for JUNS vs KAPA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

JUNS vs KAPA — Which Stock Is More Undervalued?

JUNS scores higher with a 4.7/10 quality rating vs KAPA's 4.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Jupiter Neurosciences, Inc. (JUNS) and Kairos Pharma, Ltd. (KAPA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

JUNS currently trades at $0.26 with a QOC of 4.7/10, while KAPA trades at $0.51 with a QOC of 4.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).